IGC licenses THC-based treatment for alzheimer’s

Maryland-based India Globalization Capital, Inc. (IGC) said it entered into a definitive license agreement with the University of South Florida making IGC the exclusive licensee of the US patent filing entitled “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.”

“By acquiring this patent filing, IGC is protecting a potential cannabis-based blockbuster treatment for America’s most expensive disease …” said IGC in a statement.

“THC has several known molecular pathways by which it interacts with the human body, including binding to the CB1 receptor, anti-oxidative effects, and others,” said IGC.

“The patent filing claims discovery of a new pathway: low doses of THC bind to amyloid beta plaques and prevent those plaques from aggregating on neurons, which is what occurs in Alzheimer’s disease and causes cognitive decline.”

Ram Mukunda, CEO of IGC, said securing the licensing agreement from the University of South Florida represented a major turning point for IGC as it looked to prepare several key products for clinical trials.

“We have worked hard to assemble a strong development team and a primary pipeline of four major products addressing large markets and possible blockbuster indications utilizing cannabis-based therapies,” said Mukunda.

“We are putting the finishing touches on our products, which may include filing additional patents, and we very much expect to start pursuing clinical trials for our Alzheimer’s product and others this year.”